Citations

Clear

3138 citation(s) found for "Smith, AM".

Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women
Dupont, William D. , Vierkant, Robert A. , Frank, Ryan D. , Frost, Marlene H., Winham, Stacey J. , Smith, Jeffrey R. , Page, David L., Vachon, Celine M. , Ghosh, Karthik, Denison, Lori A., Carter, Jodi M. , Hartmann, Lynn C. , Visscher, Daniel W., Radisky, Derek C. , Hoskin, Tanya L. , Degnim, Amy C. , Sanders, Melinda E. , Vachon, Celine M. , Hieken, Tina J. , Winham, Stacey J , Vierkant, Robert A , Carter, Jodi

Mayo Clinic

Cancer | June 29, 2016 | Volume: 122 | Issue: 19 | Pages: 2971-2978

10.1002/cncr.30153 | PMID 27352219 Get It

BACKGROUNDWomen with atypical hyperplasia (AH) on breast biopsy have a substantially increased risk of breast cancer (BC). Here the BC risk for the extent and subtype of AH is reported for 2 separate cohorts.METHODSAll samples containing AH were included from 2 cohorts of women with benign breast disease (Mayo Clinic and Nashville). Histology review quantified the number of foci of atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH). The BC risk was stratified for the number of AH foci within AH subtypes.RESULTSThe study included 708 Mayo AH subjects and 466 Nashville AH subjects. In the Mayo cohort, an increasing number of foci of AH was associated with a significant increase in the risk of BC both for ADH (relative risks of 2.61, 5.21, and 6.36 for 1, 2, and ≥3 foci, respectively; P for linear trend = .006) and for ALH (relative risks of 2.56, 3.50, and 6.79 for 1, 2, and ≥3 foci, respectively; P for linear trend = .001). In the Nashville cohort, the relative risks of BC for ADH were 2.70, 5.17, and 15.06 for 1, 2, and ≥3 foci, respectively (P for linear trend < .001); for ALH, the relative risks also increased but not significantly (2.61, 3.48, and 4.02, respectively; P = .148). When the Mayo and Nashville samples were combined, the risk increased significantly for 1, 2, and ≥3 foci: the relative risks were 2.65, 5.19, and 8.94, respectively, for ADH (P < .001) and 2.58, 3.49, and 4.97, respectively, for ALH (P = .001).CONCLUSIONSIn 2 independent cohort studies of benign breast disease, the extent of atypia stratified the long‐term BC risk for ADH and ALH. Cancer 2016;122:2971‐2978. © 2016 American Cancer Society.
Concurrent Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx in a Married Couple
Brobst, Tyler D. , García, Joaquín J. , Price, Katharine A. , Smith, David I., Price, Daniel L , Gao, Ge , Smith, David I., Price, Daniel L.

Mayo Clinic

Case Reports in Otolaryngology | June 23, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-4

10.1155/2016/8481235 | PMID 27418994 Get It

Background. Although alcohol and tobacco use are known risk factors for development of squamous cell carcinoma in the head and neck, human papillomavirus (HPV) has been increasingly associated with this group of cancers. We describe the case of a married couple who presented with HPV-positive oropharynx squamous cell carcinoma within two months of each other.Methods. Tumor biopsies were positive for p16 and high-risk HPV in both patients. Sanger sequencing showed a nearly identical HPV16 strain in both patients. Both patients received chemoradiation, and one patient also underwent transoral robotic tongue base resection with bilateral neck dissection.Results. Both patients showed no evidence of recurrent disease on follow-up PET imaging.Conclusions. New head and neck symptoms should be promptly evaluated in the partner of a patient with known HPV-positive oropharynx cancer. This case expands the limited current literature on concurrent presentation of HPV-positive oropharynx squamous cell carcinoma in couples.
Optimal Dose of Calcium for Treatment of Nutritional Rickets: A Randomized Controlled Trial
Thacher, Tom D. , Smith, Lauren, Isichei, Christian O., Cha, Stephen S, Pettifor, John Μ. , Fischer, Philip R. , Cha, Stephen S, Pettifor, John M , Thacher, Thomas D

Mayo Clinic

Journal of Bone and Mineral Research | June 17, 2016 | Volume: 31 | Issue: 11 | Pages: 2024-2031

10.1002/jbmr.2886 | PMID 27311415 Get It

ABSTRACT Calcium supplementation is indicated for the treatment of nutritional rickets. Our aim was to determine the optimal dose of calcium for treatment of children with rickets. Sixty-five Nigerian children with radiographically confirmed rickets were randomized to daily supplemental calcium intake of 500 mg (n = 21), 1000 mg (n = 23), or 2000 mg (n = 21). Venous blood, radiographs, and forearm areal bone density (aBMD) were obtained at baseline and at 8, 16, and 24 weeks after enrollment. The primary outcome was radiographic healing, using a 10-point radiographic severity score. The radiographic severity scores improved in all three groups, but the rate of radiographic healing (points per month) was significantly more rapid in the 1000-mg (–0.29; 95% confidence interval [CI] –0.13 to –0.45) and 2000-mg (–0.36; 95% CI –0.19 to –0.53) supplementation groups relative to the 500-mg group. The 2000-mg group did not heal more rapidly than the 1000-mg group. Of those who completed treatment for 24 weeks, 12 (67%), 20 (87%), and 14 (67%) in the 2000-mg, 1000-mg, and 500-mg groups, respectively, had achieved a radiographic score of 1.5 or less (p = 0.21). Serum alkaline phosphatase decreased and calcium increased similarly in all groups. Forearm diaphyseal aBMD improved significantly more rapidly in the 2000-mg group than in the 500-mg and 1000-mg groups (p &lt; 0.001). Daily calcium intakes of 1000 mg or 2000 mg produced more rapid radiographic healing of rickets than 500 mg, but 2000 mg did not have greater benefit than 1000 mg. Some children require longer than 24 weeks for complete healing of nutritional rickets. © 2016 American Society for Bone and Mineral Research.
Ultrasound of the Gruberi Bursa With Cadaveric and MRI Correlation
Gaetke‐Udager, Kara , Jacobson, Jon A. , Bhatti, Zeeshaan S., Smith, Jay , Parameswaran, Aishwarya, Fessell, David , Jacobson, Jon A

Mayo Clinic

American Journal of Roentgenology | June 15, 2016 | Volume: 207 | Issue: 2 | Pages: 386-391

10.2214/ajr.15.15955 | PMID 27305451 Get It

A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia
Luskin, Marlise R. , Gimotty, Phyllis A. , Smith, Catherine , Loren, Alison W. , Harrison, Jenna , Sun, Zhuoxin , Tallman, Martin S. , Paietta, Elisabeth , Litzow, Mark R. , Melnick, Ari , Levine, Ross L. , Fernández, Hugo F. , Luger, Selina M. , Wertheim, Gerald , Luskin, Marlise R , Figueroa, María E. , Carroll, Martin P , Master, Stephen R. , Melnick, Ari

Mayo Clinic

JCI Insight | June 15, 2016 | Volume: 1 | Issue: 9 | Pages: No page available

10.1172/jci.insight.87323 | PMID 27446991 Get It

BACKGROUND. Variable response to chemotherapy in acute myeloid leukemia (AML) represents a major treatment challenge. Clinical and genetic features incompletely predict outcome. The value of clinical epigenetic assays for risk classification has not been extensively explored. We assess the prognostic implications of a clinical assay for multilocus DNA methylation on adult patients with de novo AML. METHODS. We performed multilocus DNA methylation assessment using xMELP on samples and calculated a methylation statistic (M-score) for 166 patients from UPENN with de novo AML who received induction chemotherapy. The association of M-score with complete remission (CR) and overall survival (OS) was evaluated. The optimal M-score cut-point for identifying groups with differing survival was used to define a binary M-score classifier. This classifier was validated in an independent cohort of 383 patients from the Eastern Cooperative Oncology Group Trial 1900 (E1900; NCT00049517). RESULTS. A higher mean M-score was associated with death and failure to achieve CR. Multivariable analysis confirmed that a higher M-score was associated with death ( P = 0.011) and failure to achieve CR ( P = 0.034). Median survival was 26.6 months versus 10.6 months for low and high M-score groups. The ability of the M-score to perform as a classifier was confirmed in patients ≤ 60 years with intermediate cytogenetics and patients who achieved CR, as well as in the E1900 validation cohort. CONCLUSION. The M-score represents a valid binary prognostic classifier for patients with de novo AML. The xMELP assay and associated M-score can be used for prognosis and should be further investigated for clinical decision making in AML patients.
HDAC3 Is Required for the Downregulation of RORγt during Thymocyte Positive Selection
Philips, Rachael L. , Chen, Meibo W., McWilliams, Douglas C., Belmonte, Paul , Constans, Megan, Belmonte, Paul J, Constans, Megan M, Shapiro, Virginia Smith , Belmonte, Paul J

Mayo Clinic

The Journal of Immunology | June 9, 2016 | Volume: 197 | Issue: 2 | Pages: 541-554

10.4049/jimmunol.1502529 | PMID 27279370 Get It

Abstract To generate functional peripheral T cells, proper gene regulation during T cell development is critical. In this study, we found that histone deacetylase (HDAC) 3 is required for T cell development. T cell development in CD2-icre HDAC3 conditional knockout (cKO) mice (HDAC3-cKO) was blocked at positive selection, resulting in few CD4 and CD8 T cells, and it could not be rescued by a TCR transgene. These single-positive thymocytes failed to upregulate Bcl-2, leading to increased apoptosis. HDAC3-cKO mice failed to downregulate retinoic acid–related orphan receptor (ROR) γt during positive selection, similar to the block in positive selection in RORγt transgenic mice. In the absence of HDAC3, the RORC promoter was hyperacetylated. In the periphery, the few CD4 T cells present were skewed toward RORγt+ IL-17–producing Th17 cells, leading to inflammatory bowel disease. Positive selection of CD8 single-positive thymocytes was restored in RORγt-KO Bcl-xL transgenic HDAC3-cKO mice, demonstrating that HDAC3 is required at positive selection to downregulate RORγt.
MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies
Lorenzo‐Betancor, Oswaldo , Soto‐Ortolaza, Alexandra I., Walton, Ronald L., Murray, Melissa E. , Allen, Mariet , Uitti, Ryan J. , Smith, Glenn E. , Kantarci, Kejal , Lowe, Val J. , Jack, Clifford R. , Ertekin‐Taner, Nilüfer , Hassan, Anhar , Savica, Rodolfo , Petersen, Ronald C. , Parisi, Joseph E., Maraganore, Demetrius M. , Graff‐Radford, Neill R. , Ferman, Tanis J. , Ross, Owen A. , Soto‐Beasley, Alexandra I. , Labbé, Catherine, Lorenzo-Betancor, Oswaldo, Soto-Ortolaza, Alexandra I., Labbé, Catherine , Heckman, Michael G. , Wszołek, Zbigniew K. , Knopman, David S. , Boeve, Bradley F. , Dickson, Dennis W. , Jack, Clifford R , Ross, Owen A , Kantarci, Kejal , Murray, Melissa E , Ferman, Tanis J , Beasley, Alexandra I

Mayo Clinic

Alzheimer's & Dementia | June 8, 2016 | Volume: 12 | Issue: 12 | Pages: 1297-1304

10.1016/j.jalz.2016.05.002 | PMID 27287057 Get It

Abstract Introduction The MAPT H1 haplotype has been associated with several neurodegenerative diseases. We were interested in exploring the role of MAPT haplotypic variation in risk of dementia with Lewy bodies (DLB). Method We genotyped six MAPT haplotype tagging SNPs and screened 431 clinical DLB cases, 347 pathologically defined high‐likelihood DLB cases, and 1049 controls. Result We performed haplotypic association tests and detected an association with the protective H2 haplotype in our combined series (odds ratio [OR] = 0.75). We fine‐mapped the locus and identified a relatively rare haplotype, H1G, that is associated with an increased risk of DLB (OR = 3.30, P = .0017). This association was replicated in our pathologically defined series (OR = 2.26, P = .035). Discussion These results support a role for H1 and specifically H1G in susceptibility to DLB. However, the exact functional variant at the locus is still unknown, and additional studies are warranted to fully explain genetic risk of DLB at the MAPT locus.
Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP)
Antwi, Samuel O. , Su, L. Joseph , Zhang, Hongmei , Craft, Neal E. , Fontham, Elizabeth T. H., Smith, Gary J., Bensen, Jeannette T. , Mohler, James L. , Arab, Lenore , Steck, Susan E. , Hébert, James R. , Antwi, Samuel O

Mayo Clinic

The Prostate | June 8, 2016 | Volume: 76 | Issue: 12 | Pages: 1053-1066

10.1002/pros.23189 | PMID 27271547 Get It

Treatment Fidelity Among Family Health Promoters Delivering a Physical Activity and Nutrition Intervention to Immigrant and Refugee Families
Bronars, Carrie, Hanza, Marcelo M., Clark, Matthew M. , Nigon, Julie A., Weis, Jennifer A., Sia, Irene G. , Patten, Christi A. , Wieland, Mark L. , Meiers, Sonja J. , Sia, Irene G

Mayo Clinic

Health Education & Behavior | June 6, 2016 | Volume: 44 | Issue: 2 | Pages: 262-270

10.1177/1090198116650668 | PMID 27268494 Get It

Lack of treatment fidelity can be an important source of variation affecting the credibility and utility of outcomes from behavioral intervention research. Development and implementation of a well-designed treatment fidelity plan, especially with research involving underserved populations, requires careful conceptualization of study needs in conjunction with what is feasible in the population. The purpose of this article is to review a fidelity-monitoring plan consistent with the National Institutes of Health Behavior Change Consortium guidelines (e.g., design, training, delivery, receipt, and enactment) for an intervention trial designed to improve physical activity and nutrition among immigrant and refugee families. Description of the fidelity monitoring plan is provided and challenges related to monitoring treatment fidelity in a community-based participatory intervention for immigrant and refugee families are discussed.
Establishing high‐quality reference values for nerve conduction studies: A report from the normative data task force of the American Association Of Neuromuscular & Electrodiagnostic Medicine
Dillingham, Timothy R. , Chen, Shan , Andary, Michael , Buschbacher, Ralph M., Toro, David Del, Smith, Benn, Zimmermann, Kuno P., So, Yuen T., Smith, Benn E.

Mayo Clinic

Muscle & Nerve | May 30, 2016 | Volume: 54 | Issue: 3 | Pages: 366-370

10.1002/mus.25204 | PMID 27238858 Get It

ABSTRACT Introduction: There are not uniform standards for nerve conduction testing across the United States. The objective of this study is to present a set of methodologically sound criteria to evaluate the literature for the purpose of identifying high‐quality normative nerve conduction studies (NCS) suitable for widespread use. Methods: The Normative Data Task Force (NDTF) was formed to review published studies on methodological issues related to NCS. A set of criteria was then developed to evaluate the literature. These criteria and their rationale are described. Results: We identified 7 key issues that reflect high quality in NCS. For each issue, specific review criteria were developed. Conclusion: Rigorous criteria enable identification of high‐quality studies dealing with nerve conduction reference values. This represents the first step toward the overarching goal of recommending NCS techniques and reference values for electrodiagnostic medicine. Muscle Nerve 54 : 366–370, 2016